Changes

==References==

==References==

1. Jennings, G. T. et al. Cytosolic NADP (+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J. Biol. Chem. 269, 23128–23134 (1994). PMID: 8083215

1. Jennings GT, et al., (1994). Cytosolic NADP (+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J Biol Chem 269:23128–23134, PMID 8083215.

2. Luo, H., Shan, X. & Wu, J. Expression of human mitochondrial NADP‐dependent isocitrate dehydrogenase during lymphocyte activation. J. Cell. Biochem. 60, 495–507 (1996). PMID: 8707889

2. Luo H, et al., (1996). Expression of human mitochondrial NADP‐dependent isocitrate dehydrogenase during lymphocyte activation. J Cell Biochem 60:495–507, PMID 8707889.

3. Nekrutenko, A., Hillis, D. M., Patton, J. C., Bradley, R. D. & Baker, R. J. Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol. Biol. Evol. 15, 1674–1684 (1998). PMID: 9866202

3. Nekrutenko A, et al., (1998). Cytosolic isocitrate dehydrogenase in humans, mice, and voles and phylogenetic analysis of the enzyme family. Mol Biol Evol 15:1674–1684, PMID 9866202.

4. Ceccarelli, C., Grodsky, N. B., Ariyaratne, N., Colman, R. F. & Bahnson, B. J. Crystal Structure of Porcine Mitochondrial NADP+-dependent Isocitrate Dehydrogenase Complexed with Mn2+ and Isocitrate. INSIGHTS INTO THE ENZYME MECHANISM. J. Biol. Chem. 277, 43454–43462 (2002). PMID: 12207025

4. Ceccarelli C, et al., (2002). Crystal Structure of Porcine Mitochondrial NADP+-dependent Isocitrate Dehydrogenase Complexed with Mn2+ and Isocitrate. Insights into the enzyme mechanism. J Biol Chem 277:43454–43462, PMID 12207025.

5. Ward, P. S. et al. The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 17, 225–234 (2010). PMID: 20171147

5. Ward PS, et al., (2010). The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 17:225–234, PMID 20171147.

6. Comte, B., Vincent, G., Bouchard, B., Benderdour, M. & Des Rosiers, C. Reverse flux through cardiac NADP + -isocitrate dehydrogenase under normoxia and ischemia. Am. J. Physiol.-Heart Circ. Physiol. 283, H1505–H1514 (2002). PMID: 12234803

6. Comte B, et al., (2002). Reverse flux through cardiac NADP + -isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol-Heart Circ Physiol 283:H1505–H1514, PMID 12234803.

7. Sazanov, L. A. & Jackson, J. B. Proton-translocating transhydrogenase and NAD- and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria. FEBS Lett. 344, 109–116 (1994). PMID: 8187868

7. Sazanov LA and Jackson JB, (1994). Proton-translocating transhydrogenase and NAD- and NADP-linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria. FEBS Lett 344:109–116, PMID 8187868.

8. Reitman, Z. J. & Yan, H. Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. JNCI J. Natl. Cancer Inst. 102, 932–941 (2010). PMID: 20513808

8. Reitman ZJ and Yan H (2010). Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. JNCI J Natl Cancer Inst 102:932–941, PMID 20513808.

9. Mailloux, R. J. et al. The Tricarboxylic Acid Cycle, an Ancient Metabolic Network with a Novel Twist. PLoS ONE 2, e690 (2007). PMID: 17668068

9. Mailloux RJ, et al., (2007). The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE 2:e690, PMID 17668068.

10. Lee, S. M. et al. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 32, 1185–1196 (2002). PMID: 12031902

10. Lee SM, et al., (2002). Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32:1185–1196, PMID 12031902.

11. Lee, S. ‐H. et al. Role of NADP+‐dependent isocitrate dehydrogenase (NADP+‐ICDH) on cellular defence against oxidative injury by γ‐rays. Int. J. Radiat. Biol. 80, 635–642 (2004). PMID: 15586883

11. Lee S‐H, et al., (2004). Role of NADP+‐dependent isocitrate dehydrogenase (NADP+‐ICDH) on cellular defence against oxidative injury by γ‐rays. Int J Radiat Biol 80:635–642, PMID 15586883.

12. Lee, J. H., Kim, S. Y., Kil, I. S. & Park, J.-W. Regulation of Ionizing Radiation-induced Apoptosis by Mitochondrial NADP + -dependent Isocitrate Dehydrogenase. J. Biol. Chem. 282, 13385–13394 (2007). PMID: 17350954

12. Lee JH, et al., (2007). Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem 282:13385–13394, PMID 17350954.

13. Shin, S. W., Kil, I. S. & Park, J.-W. Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase by small interfering RNA enhances heat shock-induced apoptosis. Biochem. Biophys. Res. Commun. 366, 1012–1018 (2008). PMID: 18096511

13. Shin SW, et al., (2008). Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase by small interfering RNA enhances heat shock-induced apoptosis. Biochem Biophys Res Commun 366:1012–1018, PMID 18096511.

14. Kil, I. S., Kim, S. Y., Lee, S. J. & Park, J.-W. Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-α and anticancer drugs. Free Radic. Biol. Med. 43, 1197–1207 (2007). PMID: 17854715

14. Kil IS, et al., (2007). Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-α and anticancer drugs. Free Radic Biol Med 43:1197–1207, PMID 17854715.

15. Kranendijk, M. et al. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330, 336 (2010). PMID: 20847235

15. Kranendijk M, et al., IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330:336, PMID 20847235.

16. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009). PMID: 23532369

16. Yan H, et al., (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773, PMID 23532369.

17. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. (Berl.) 118, 469–474 (2009). PMID: 19554337

17. Hartmann C, et al., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (Berl) 118:469–474, PMID 19554337.

18. Amary, M. F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343 (2011). PMID: 21598255

18. Amary MF, et al., (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334–343, PMID 21598255.

19. Borger, D. R. et al. Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. The Oncologist 17, 72–79 (2012). PMID: 22180306

19. Borger DR, et al., (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist 17:72–79, PMID 22180306.

20. Houillier, C. et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75, 1560–1566 (2010). PMID: 20975057

20. Houillier C, et al., (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–1566, PMID 20975057.

21. Lugowska, I. et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J. Cancer 9, 998–1005 (2018). PMID: 29581779

21. Lugowska, I. et al. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. J. Cancer 9, 998–1005 (2018). PMID: 29581779